Who manufactures Crenessity (Crinecerfont)?

Crinecerfont bulk supplier for pharma manufacturers

Crinecerfont 50 mg, 100 mg, 50 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Capsule / Oral solution

Available Strengths: 50 mg, 100 mg, 50 mg/mL

Reference Brands: Crenessity (USA)

Crinecerfont is used in addition to glucocorticoid replacement therapy in adults and children aged 4 years and older with classic Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency. It works by blocking CRF1 receptors, which helps reduce the over-production of adrenocorticotropic hormone (ACTH) and subsequently lowers excess adrenal androgens. This enables better control of the disease and potentially lower steroid doses, reducing long term complications of glucocorticoid over-exposure.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Crinecerfont? List it or send an offer →

Product Description:

Crinecerfont is a corticotropin-releasing factor type 1 receptor antagonist, and the first drug to treat classic congenital adrenal hyperplasia by addressing the cause of the androgen excess rather than suppressing it with more steroid. In 21-hydroxylase deficiency the adrenal cannot make cortisol, so the pituitary drive never switches off and ACTH pushes the gland into overproducing androgens. Blocking the CRF1 receptor reduces that drive at its origin.

It is indicated as an adjunct to glucocorticoid replacement in adults and children aged four and over with classic congenital adrenal hyperplasia. The clinical value is that it allows steroid doses to be reduced towards physiological replacement while androgen control improves, which matters because decades of supraphysiological glucocorticoid exposure cause obesity, osteoporosis, glucose intolerance and growth suppression. Fatigue, headache and dizziness are the common adverse effects; glucocorticoid cover must still be increased during illness or stress.

Sourcing notes. Recently approved originator product, on patent, with approval so far limited to a small number of territories — confirm registration status before quoting. Capsules and an oral solution for paediatric dosing are distinct presentations. Note that this is an endocrine product, not an oncology one.

How Crinecerfont is supplied today, and licensing ahead of patent expiry

Crinecerfont is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Crinecerfont, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Crinecerfont supply →

Back to Listing

Frequently Asked Questions

Crenessity (Crinecerfont) is developed and sold by Neurocrine Biosciences. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.